WEBULL
News
TXG
17.77
-2.09%
-0.38
10x Genomics (TXG) Is Down 5.5% After Morgan Stanley Downgrade Has The Bull Case Changed?
Simply Wall St · 4h ago
10x Genomics (TXG): Assessing Valuation After a 36% One-Month Share Price Rebound
Simply Wall St · 1d ago
3 Unprofitable Stocks with Questionable Fundamentals
Barchart · 2d ago
This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday
Benzinga · 4d ago
Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls
TipRanks · 4d ago
10x Genomics Price Target Raised to $20.00/Share From $17.00 by Morgan Stanley
Dow Jones · 4d ago
10x Genomics Cut to Equal-Weight From Overweight by Morgan Stanley
Dow Jones · 4d ago
Morgan Stanley Downgrades 10x Genomics to Equal-Weight, Raises Price Target to $20
Benzinga · 4d ago
10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley
TipRanks · 4d ago
10x Genomics downgraded to Equal Weight from Overweight at Morgan Stanley
TipRanks · 4d ago
Cathie Wood's Ark Invest weekly recap: Boosts AI and Crypto Bets, Trims Palantir, GitLab, and AMD
Seeking Alpha · 5d ago
Weekly Report: what happened at TXG last week (1124-1128)?
Weekly Report · 5d ago
10x Genomics (TXG) Is Up 19.8% After Pan-Cancer Atlas Collaboration With Garvan and University of Tokyo
Simply Wall St · 11/27 15:40
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know
Barchart · 11/24 18:16
Weekly Report: what happened at TXG last week (1117-1121)?
Weekly Report · 11/24 09:20
10x Genomics (TXG) Valuation in Focus After Joining Pioneering Asia-Pacific Cancer Research Alliance
Simply Wall St · 11/23 15:23
Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know
Barchart · 11/21 17:44
Will 10x Genomics' (TXG) Role in ASTRA Shift Its Competitive Edge in Precision Oncology?
Simply Wall St · 11/20 12:26
10x Genomics Joins Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas
Reuters · 11/18 14:02
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium
PR Newswire · 11/18 14:00
More
Webull provides a variety of real-time TXG stock news. You can receive the latest news about 10X Genomics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.